דילוג לתוכן הראשי
xMedica

NCT07439653ClinicalTrials.gov

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

מגייסמקבל משתתפים כעת, לפי רשומת המרשם.
יצירת קשר עם המחקר

בקצרה

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

שלב 1 / שלב 2דרושים 155 משתתפים9 אתריםמדינה אחת

קטגוריות

רשום במרשם אחד

מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.

מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.

מתעניינים במחקר הזה?

התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-02-27; recorded start 2026-03-31
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 9 other studies in this databaseCounted from the lead sponsor named in the record (TORL Biotherapeutics, LLC)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Non-randomised allocation

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 3 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleSMALL

A small study: 155 participants (target), run at 9 sites.

How this score is built
  • Enrolment21/40

    155 participants (target)

  • Site count6/25

    3 sites

  • Country count0/15

    Single country

  • Planned duration9/10

    Planned over about 43 months

  • Sponsor scale3/10

    TORL Biotherapeutics, LLC has led 10 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

תקציר

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

מצבים רפואיים

  • Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

זכאות

זכאות
מיןהכול
גילאים18 Years – ללא מקסימום
מתנדבים בריאיםלא

זכאות כפי שנכתבה במרשם

Inclusion Criteria: * Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT. * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. * At least 1 measurable lesion per Lugano criteria. * Tumor tissue is available. * Adequate organ function Exclusion Criteria: * T-cell lymphoma * CLL or SL * Burkitt lymphoma and high-grade B-cell lymphoma * CNS involvement * Peripheral neuropathy \> Grade 2 * Uncontrolled medical conditions * Viral infections

זכאות במשפטים פשוטים

הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.

תכנון המחקר

תכנון המחקר
סוג המחקרהתערבותי
שלבשלב 1 / שלב 2
הקצאהלא אקראי
מודל ההתערבותSEQUENTIAL
מטרה ראשיתTREATMENT
הסתרהNONE (0)
גיוסדרושים 155 משתתפים

נותן חסות ושותפים

  • TORL Biotherapeutics, LLC נותן חסות

זרועות והתערבויות

  • Part 1: Monotherapy Dose EscalationEXPERIMENTAL

    TORL-5-700 Administered once every three weeks

  • Part 2: Monotherapy ExpansionEXPERIMENTAL

    TORL-5-700 at MTD/RP2D Administered once every three weeks

  • Part 3: Combination EvaluationEXPERIMENTAL

    TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent

התערבויות

  • תרופה TORL-5-700

    Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks

  • תרופה TORL-5-700 at MTD/RP2D

    Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks

  • תרופה TORL-5-700 at MTD/RP2D in combination with another agent

    Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent

מדדי תוצאה

  1. מדד תוצאה ראשוני

    Evaluate the safety of TORL-5-700 as a monotherapy

    Assessment of adverse events according to NCI-CTCAE Version 5.0

    מסגרת זמן though study completion, an average of 2.5 years

  2. מדד תוצאה ראשוני

    Assess the antitumor activity of TORL-5-700 as monotherapy

    Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria

    מסגרת זמן though study completion, an average of 2.5 years

  3. מדד תוצאה ראשוני

    Evaluate the safety of TORL-5-700 in combination with other agents

    Assessment of adverse events according to NCI-CTCAE Version 5.0

    מסגרת זמן though study completion, an average of 2.5 years

  4. מדד תוצאה ראשוני

    Determine the Maximum Tolerated Dose (MTD)

    Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT)

    מסגרת זמן 21 days from the start of treatment

  5. מדד תוצאה ראשוני

    Determine the Recommended Phase 2 Dose (RP2D)

    Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities

    מסגרת זמן 21 days from the start of treatment

  6. מדד תוצאה משני

    Maximum Serum Concentration of TORL-5-700 (Cmax)

    Pk assessment

    מסגרת זמן though end of study treatment, an average of 5 months

  7. מדד תוצאה משני

    Maximum Serum Concentration of TORL-5-700 (Cmax) in combination with other agents

    Pk assessment

    מסגרת זמן though end of study treatment, an average of 5 months

  8. מדד תוצאה משני

    Terminal Half-life (t1/2) of Serum TORL-5-700

    Pk assessment

    מסגרת זמן though end of study treatment, an average of 5 months

  9. מדד תוצאה משני

    Terminal Half-life (t1/2) of Serum TORL-5-700 in combination with other agents

    Pk assessment

    מסגרת זמן though end of study treatment, an average of 5 months

  10. מדד תוצאה משני

    Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration

    Pk assessment

    מסגרת זמן though end of study treatment, an average of 5 months

  11. מדד תוצאה משני

    Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration in combination with other agents

    Pk assessment

    מסגרת זמן though end of study treatment, an average of 5 months

  12. מדד תוצאה משני

    Clearance (CL) of TORL-5-700

    Pk assessment

    מסגרת זמן though end of study treatment, an average of 5 months

  13. מדד תוצאה משני

    Clearance (CL) of TORL-5-700 in combination with other agents

    Pk assessment

    מסגרת זמן though end of study treatment, an average of 5 months

  14. מדד תוצאה משני

    Volume of distribution of TORL-5-700

    PK assessment

    מסגרת זמן though end of study treatment, an average of 5 months

  15. מדד תוצאה משני

    Volume of distribution of TORL-5-700 in combination with other agents

    PK assessment

    מסגרת זמן though end of study treatment, an average of 5 months

  16. מדד תוצאה משני

    Immunogenicity of TORL-5-700

    Immunogenicity will be measured by incidence of treatment emergent ADAs

    מסגרת זמן though end of study treatment, an average of 5 months

  17. מדד תוצאה משני

    Immunogenicity of TORL-5-700 in combination with other agents

    Immunogenicity will be measured by incidence of treatment emergent ADAs

    מסגרת זמן though end of study treatment, an average of 5 months

  18. מדד תוצאה משני

    Assess the preliminary antitumor activity of TORL-5-700 in combination with other agents

    Assess the antitumor activity of TORL-5-700 in combination with other agents using Cheson (2014) disease grading criteria

    מסגרת זמן though study completion, an average of 2.5 years

תאריכים

תאריכים
תאריך התחלה31 במרץ 2026 (בפועל)
סיום ראשוני31 במרץ 2029 (משוער)
סיום30 בספטמבר 2029 (משוער)
פורסם לראשונה27 בפברואר 2026 (בפועל)
עודכן לאחרונה28 בספטמבר 2026
התוצאות פורסמולא צוין ברשומת המרשם
המצב אומת לאחרונהאוגוסט 2026

בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.

מיקומים

9 אתרים מגייסים

United States

United States
מתקןעירמדינה או אזורמצב
University of Texas Southwestern Medical CenterDallasTexasמגייס
Providence Medical FoundationFullertonCaliforniaמגייס
University of Iowa Health CareIowa CityIowaמגייס
Cancer and Blood Specialty Clinic, Los AlamitosLos AlamitosCaliforniaמגייס
University of California Miami, Sylvester Comprehensive Cancer CenterMiamiFloridaמגייס
Sarah Cannon Research InstituteNashvilleTennesseeמגייס
UCLASanta MonicaCaliforniaמגייס
Stanford UniversityStanfordCaliforniaמגייס
Cancer Center of Kansas, WichitaWichitaKansasמגייס

מסמכי המחקר

לא צורפו מסמכים ברשומת מרשם זו.

שינויים לאורך זמן

  1. 28 בספטמבר 2026

    אתר נוסף

    3 sites added (9 total)

    69

  2. 24 באוגוסט 2026

    אתר נוסף

    3 sites added (6 total)

    36